These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Bonnick SL; Shulman L Am J Med; 2006 Apr; 119(4 Suppl 1):S25-31. PubMed ID: 16563938 [TBL] [Abstract][Full Text] [Related]
3. Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Reginster JY; Collette J; Neuprez A; Zegels B; Deroisy R; Bruyere O Bone; 2008 May; 42(5):832-6. PubMed ID: 18316258 [TBL] [Abstract][Full Text] [Related]
4. Anti-resorptives in the management of osteoporosis. Miller PD Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):849-68. PubMed ID: 19028360 [TBL] [Abstract][Full Text] [Related]
5. Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? Seeman E Bone; 2007 Sep; 41(3):308-17. PubMed ID: 17644058 [TBL] [Abstract][Full Text] [Related]
6. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis]. Wada S; Fukawa T; Kamiya S Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665 [TBL] [Abstract][Full Text] [Related]
8. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. Armamento-Villareal R; Napoli N; Panwar V; Novack D N Engl J Med; 2006 Nov; 355(19):2048-50. PubMed ID: 17093260 [No Abstract] [Full Text] [Related]
9. Biomarkers of bone health and osteoporosis risk. Eastell R; Hannon RA Proc Nutr Soc; 2008 May; 67(2):157-62. PubMed ID: 18412989 [TBL] [Abstract][Full Text] [Related]
10. Skeletal morbidity in inflammatory bowel disease. van Hogezand RA; Hamdy NA Scand J Gastroenterol Suppl; 2006; (243):59-64. PubMed ID: 16782623 [TBL] [Abstract][Full Text] [Related]
11. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options. De Nijs RN Minerva Med; 2008 Feb; 99(1):23-43. PubMed ID: 18299694 [TBL] [Abstract][Full Text] [Related]
12. Assessing fracture risk and effects of osteoporosis drugs: bone mineral density and beyond. Davison KS; Kendler DL; Ammann P; Bauer DC; Dempster DW; Dian L; Hanley DA; Harris ST; McClung MR; Olszynski WP; Yuen CK Am J Med; 2009 Nov; 122(11):992-7. PubMed ID: 19854322 [TBL] [Abstract][Full Text] [Related]
13. Is bone mineral density predictive of fracture risk reduction? Cefalu CA Curr Med Res Opin; 2004 Mar; 20(3):341-9. PubMed ID: 15025843 [TBL] [Abstract][Full Text] [Related]
15. [Monitoring anti-osteoporotic therapy: bone mineral density or markers of bone turnover]. Pedersen SB; Rand MS; Eiken PA; Jørgensen NR Ugeskr Laeger; 2018 Aug; 180(32):. PubMed ID: 30070630 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744 [TBL] [Abstract][Full Text] [Related]
17. Are beta-blockers useful in the prevention of osteoporotic fractures? Pérez-Castrillón JL; De Luis DA; Duenas-Laita A Eur Rev Med Pharmacol Sci; 2009; 13(3):157-62. PubMed ID: 19673165 [TBL] [Abstract][Full Text] [Related]
18. [Evaluation methods of therapeutic effects of drugs for osteoporosis]. Ishibashi H Clin Calcium; 2012 Jun; 22(6):890-5. PubMed ID: 22653030 [TBL] [Abstract][Full Text] [Related]
19. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Cramer JA; Silverman S Am J Med; 2006 Apr; 119(4 Suppl 1):S12-7. PubMed ID: 16563936 [TBL] [Abstract][Full Text] [Related]
20. Prevention and treatment of senile osteoporosis and hip fractures. Duque G; Demontiero O; Troen BR Minerva Med; 2009 Feb; 100(1):79-94. PubMed ID: 19277006 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]